.png "Nant Health (NASDAQ: NH)")
Canaccord Genuity analyst Richard Close maintained a Hold rating on Nant Health (NASDAQ: NH) on June 29. The company’s shares closed yesterday at $3.46.
According to TipRanks.com, Close is a 5-star analyst with an average return of 13.9% and a 61.5% success rate. Close covers the Services sector, focusing on stocks such as Envision Healthcare, Hms Holdings Corp, and Evolent Health.
The word on The Street in general, suggests a Hold analyst consensus rating for Nant Health.
See today’s analyst top recommended stocks >>
Based on Nant Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $22.17 million. In comparison, last year the company had a GAAP net loss of $70.06 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NantHealth, Inc. ooperates as an evidence-based, personalized healthcare company, which provides treatment for critical diseases such as cancer. It is based on personalized healthcare approach that integrates novel diagnostics with large scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine.
